(Updated with more details)
just disclosed partial results from the pivotal study of T-DM1 in third-line breast cancer patients that's to be presented at a medical meeting on Saturday.
The objective response rate in the study was 32.7%, assessed by independent review, for the 110 breast cancer patients enrolled in the study.
These results are better than the earlier, similar
phase II study of T-DM1
in which 25% of patients responded. A subset of patients in this earlier study with confirmed Her-2 positive status had a 32% response rate to T-DM1.
ImmunoGen made the disclosure today in an 8-k filing with the
Securities and Exchange Commission
. No other details from the study were provided.
, which owns the rights to T-DM1, conducted the study. The company said it plans to seek regulatory approval for T-DM1 if the results from the study were positive.
T-DM1 is a second-generation version of Roche/Genentech's blockbuster breast cancer drug Herceptin. It consists of Herceptin (also known as trastuzumab) linked to a tumor-killing chemotherapy payload developed by ImmunoGen.
-- Reported by Adam Feuerstein in Boston
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.